Neil Kumar - 29 Oct 2021 Form 3/A - Amendment Insider Report for LianBio (LIANY)

Reporting relationship: Director
Issuer ticker: LIANY
Reported as of: 29 Oct 2021
Net transaction value: $0
SEC form: 3/A - Amendment
Accepted by SEC: 09 Nov 2021, 15:05:16 UTC
Original report date: 29 Oct 2021
Prior SEC filing: 18 Aug 2021
Next SEC filing: 18 Nov 2021
Source filing: View source filing
Reporting owner signature: By: /s/ Angela Chen, Attorney-in-Fact

Key filing fact

Neil Kumar filed Form 3/A - Amendment for LianBio (LIANY) on 09 Nov 2021.

Key facts

This page summarizes Neil Kumar's Form 3/A - Amendment filing for LianBio (LIANY).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 09 Nov 2021, 15:05.

Change

Previous filing in this sequence was filed on 18 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LIAN holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,002,792
Date: 29 Oct 2021
Ownership: By BridgeBio Pharma LLC
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares are held by BridgeBio Pharma LLC, a wholly-owned subsidiary of BridgeBio Pharma, Inc. Dr. Neil Kumar is the President and Chief Executive Officer and a director of BridgeBio Pharma, Inc., and as a result may be deemed to share voting and investing power over these Ordinary Shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC remarks

Exhibit List: Exhibit 24 - Power of Attorney